Focus on HIV Care

Back to articles

Update on Triple NRTI Therapy, Rosiglitazone Treatment of ADRs

KEY POINT

Poor responses have been noted recently in patients with HIV infection who were treated with multidrug, once-daily combinations of nucleoside reverse transcriptase inhibitors (NRTIs) and in those treated with thiazolidinediones for antiretroviral-associated lipoatrophy.

SOURCES

Jemsek J et al. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., February 9, 2004.

Landman R et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., February 9, 2004.

Elion R et al. COL40263: resistance and efficacy of once-daily Trizivir and tenofovir DF in antiretroviral naive subjects. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., February 9, 2004.

Carr A et al., for the Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet. 2004;363:429–38.